Diroximel fumarate

From WikiProjectMed
Jump to navigation Jump to search

Diroximel fumarate
Diroximel fumarate.png
Names
Trade namesVumerity
Other namesALKS-8700
Clinical data
Main usesRelapsing forms of multiple sclerosis (MS)[1]
Side effectsFlushing, abdominal pain, diarrhea, nausea[1]
Routes of
use
By mouth
External links
AHFS/Drugs.comMonograph
US NLMDiroximel fumarate
MedlinePlusa620002
Legal
License data
Legal status
Chemical and physical data
FormulaC11H13NO6
Molar mass255.226 g·mol−1
3D model (JSmol)
  • COC(=O)C=CC(=O)OCCN1C(=O)CCC1=O
  • InChI=1S/C11H13NO6/c1-17-10(15)4-5-11(16)18-7-6-12-8(13)2-3-9(12)14/h4-5H,2-3,6-7H2,1H3/b5-4+
  • Key:YIMYDTCOUQIDMT-SNAWJCMRSA-N

Diroximel fumarate, sold under the brand name Vumerity, is a medication used to treat relapsing forms of multiple sclerosis (MS).[1] This includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.[1] It is taken by mouth.[1]

Common side effects include flushing, abdominal pain, diarrhea, and nausea.[1] Other side effects may include anaphylaxis, progressive multifocal leukoencephalopathy, herpes zoster, liver problems, and low lymphocytes.[1] Use in pregnancy may harm the baby.[2] It works after the body converts it into monomethyl fumarate (MMF).[3]

Diroximel fumarate was approved for medical use in the United States in 2019.[3] While it was approved in Europe and the United Kingdom in 2021 it is not yet commercially available.[3] In the United States it costs about 7,900 USD per day as of 2021.[4]

Medical uses

It is used for the treatment of relapsing forms of multiple sclerosis (MS).[1][5][6]

Dosage

It is started at 231 mg twice per day for a week.[1] It is than taken as 462 mg twice per day.[1]

Society and culture

This drug was formulated by Alkermes in collaboration with Biogen.[7]

References

  1. 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 "Vumerity- diroximel fumarate capsule". DailyMed. Archived from the original on 5 February 2021. Retrieved 1 February 2021.
  2. "Diroximel fumarate Pregnancy and Breastfeeding Warnings". Archived from the original on 14 February 2021. Retrieved 26 December 2021.
  3. 3.0 3.1 3.2 "Vumerity · Relapsing remitting multiple sclerosis (MS)". Archived from the original on 19 May 2021. Retrieved 26 December 2021.
  4. "Vumerity Prices, Coupons and Patient Assistance Programs". Retrieved 26 December 2021.
  5. Wang Y, Bhargava P (July 2020). "Diroximel fumarate to treat multiple sclerosis". Drugs of Today (Barcelona, Spain : 1998). 56 (7): 431–437. doi:10.1358/dot.2020.56.7.3151521. PMID 32648853.
  6. Kourakis S, Timpani CA, de Haan JB, Gueven N, Fischer D, Rybalka E (October 2020). "Dimethyl Fumarate and Its Esters: A Drug with Broad Clinical Utility?". Pharmaceuticals (Basel, Switzerland). 13 (10): 306. doi:10.3390/ph13100306. PMC 7602023. PMID 33066228.
  7. "Archive copy". Archived from the original on 28 August 2021. Retrieved 30 July 2021.{{cite web}}: CS1 maint: archived copy as title (link)

External links

Identifiers:
  • "Diroximel fumarate". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on 28 August 2021. Retrieved 30 July 2021.